Nitazoxanide in the Treatment of Intestinal Parasitic Infections in Children: A Systematic Review and Meta-Analysis
- PMID: 31833040
- DOI: 10.1007/s12098-019-03098-w
Nitazoxanide in the Treatment of Intestinal Parasitic Infections in Children: A Systematic Review and Meta-Analysis
Abstract
Objectives: To evaluate the efficacy and safety of nitazoxanide in intestinal parasitic infections in children.
Methods: Four databases, PubMed, EMBASE, Web of Science and Cochrane Library, have been systematically searched from the inception of each database up to March 1st, 2019. The enrolled studies were limited to randomized clinical trials in children, comparing nitazoxanide with placebo or other antiparasitic drugs. The data extraction and quality assessment of pooled studies were conducted by two reviewers independently. For meta-analysis, Stata12.0 was used and a randomized effect model or a fixed effect model was selected according to the outcomes of heterogeneity test.
Results: A total of 1645 subjects in 13 randomized controlled trials (RCTs) were enrolled, including 768 cases in the trial group and 877 cases in the control group. The effect of nitazoxanide vs. placebo and other antiparasitic drugs on the excretion rate of pathogens was uncertain (OR = 2.06, 95%CI [1.01,4.20], P = 0.047; I2 = 84.7%; very low quality evidence). Compared with placebo, subgroup analysis suggested that nitazoxanide could significantly improve the excretion rate of pathogens (OR = 7.01, 95%CI [1.82,26.94], P = 0.005; I2 = 79.1%; moderate quality evidence), while it made little or no difference compared with antiparasitic drugs (OR = 0.72, 95%CI [0.47,1.09], P = 0.124; I2 = 33.1%; low quality evidence). Meanwhile, nitazoxanide might increase the remission rate of diarrhea with OR = 5.12, 95%CI [2.00,13.08], P = 0.001; I2 = 72.3%; low quality evidence). However, it might also increase the rate of adverse events (OR = 1.47, 95%CI [1.05,2.07], P = 0.026; I2 = 44.7%; low quality evidence).
Conclusions: The authors are uncertain whether or not nitazoxanide could improve the excretion rate of pathogens. Based on low-certainty evidence, nitazoxanide may improve the remission rate of diarrhea in children with intestinal parasite infections, but it may be associated with an increased risk of adverse reactions. Hence, more RCTs with a low risk of bias are still needed to assess the efficacy and safety of nitazoxanide.
Keywords: Children; Intestinal parasitic infections; Meta-analysis; Nitazoxanide.
Comment in
-
Nitazoxanide: Jack of All, Master of None?Indian J Pediatr. 2020 Jan;87(1):4-5. doi: 10.1007/s12098-019-03131-y. Epub 2019 Dec 4. Indian J Pediatr. 2020. PMID: 31802326 No abstract available.
Similar articles
-
Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa.Am J Trop Med Hyg. 1997 Jun;56(6):637-9. doi: 10.4269/ajtmh.1997.56.637. Am J Trop Med Hyg. 1997. PMID: 9230795 Clinical Trial.
-
Antibiotics for induction and maintenance of remission in Crohn's disease.Cochrane Database Syst Rev. 2019 Feb 7;2(2):CD012730. doi: 10.1002/14651858.CD012730.pub2. Cochrane Database Syst Rev. 2019. PMID: 30731030 Free PMC article.
-
Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).Evid Based Child Health. 2013 Jan;8(1):57-109. doi: 10.1002/ebch.1893. Evid Based Child Health. 2013. PMID: 23878124 Review.
-
Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial.Lancet. 2002 Nov 2;360(9343):1375-80. doi: 10.1016/S0140-6736(02)11401-2. Lancet. 2002. PMID: 12423984 Clinical Trial.
-
Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.Expert Rev Anti Infect Ther. 2022 Dec;20(12):1615-1622. doi: 10.1080/14787210.2022.2142117. Epub 2022 Nov 3. Expert Rev Anti Infect Ther. 2022. PMID: 36317748
Cited by
-
Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model.Pharmaceuticals (Basel). 2023 Jun 1;16(6):826. doi: 10.3390/ph16060826. Pharmaceuticals (Basel). 2023. PMID: 37375773 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical